Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


August 04, 2015 2:34 PM ET

Pharmaceuticals

Company Overview of Fresenius Kabi USA, LLC

Company Overview

Fresenius Kabi USA, LLC, an integrated pharmaceutical company, develops, manufactures, and markets injectable pharmaceutical products for customers in North America. The company primarily focuses on the anesthetic/analgesic, anti-infective, critical care, and oncology markets for use in hospitals, long-term care facilities, alternate care sites, and clinics. It manufactures various dosages and formulations in the areas of cardiac care, dialysis, emergency, intensive care, OB/GYN, operating room, oncology, orthopedics, pediatrics, psychiatry, and radiology. The company was formerly known as APP Pharmaceuticals, LLC and changed its name to Fresenius Kabi USA, LLC in August 2012. The company wa...

1501 East Woodfield Road

Suite 300 East

Schaumburg, IL 60173-5837

United States

Founded in 1996

Phone:

847-969-2700

Fax:

847-413-8571

Key Executives for Fresenius Kabi USA, LLC

President and Chief Executive Officer
Executive Vice President and Chief Financial Officer
Chief Operating Officer and Executive Vice President
Age: 60
Chief Scientific Officer and Executive Vice President
Age: 54
Executive Vice President and General Counsel
Age: 58
Compensation as of Fiscal Year 2015.

Fresenius Kabi USA, LLC Key Developments

Caplin Point Laboratories Limited and Fresenius Kabi USA, LLC Enter into License and Distribution Agreement

Caplin Point Laboratories Ltd. has announced that a license and distribution agreement has been made and entered by and between Caplin Point Laboratories Limited, India and Fresenius Kabi USA, LLC, a Delaware Limited Liability Company. Under this agreement, Caplin Point shall be responsible for developing and manufacturing identified parenteral products whereas Fresenius Kabi USA shall be holding these ANDAs and commercialize the same in USA. This is a product specific agreement for United States of America. Currently two products are featuring in the contract.

Fresenius Kabi Receives from FDA for Kabiven® and Perikabiven®

Fresenius Kabi announced it has received approval from the U.S. Food and Drug Administration for Kabiven® and Perikabiven®, parenteral nutrition (PN) products in a three-chamber bag – the only container of its kind available in the United States. Kabiven and Perikabiven are intravenously infused solutions of lipids, dextrose, amino acids and electrolytes in three-chamber parenteral nutrition bags that efficiently deliver these nutrients in volumes and concentrations that meet the nutritional needs of most patients. The unique three-chamber bag simplifies the delivery of parenteral nutrition by providing a premixed solution that is shelf-stable until activated for patient use. Outside the United States, Kabiven is sold in more than 85 countries and has been used to treat approximately 9 million patients since its initial marketing authorization in 1999.

Cadence Pharmaceuticals, Inc. Enters into Settlement Agreement with Fresenius Kabi USA, LLC

Cadence Pharmaceuticals Inc. has entered into settlement and license agreements with Fresenius Kabi USA, LLC, resolving pending patent litigation involving OFIRMEV(R) (acetaminophen) injection. The companies are not disclosing specific terms of the settlement and license agreements. Cadence had filed suit against Fresenius Kabi in January 2013. Other details of the settlement are confidential, and the settlement is subject to submission to the Federal Trade Commission and the U.S. Department of Justice. The settlement and license agreements will become effective upon the entry by the U.S. District Court of an order dismissing with prejudice the litigation with respect to Fresenius Kabi.

Similar Private Companies By Industry

Company Name Region
MeriCal, Inc. United States
Sentinella Pharmaceuticals, Inc. United States
Targeted Cell Therapies LLC United States
Libertas Pharma Inc. United States
Verne Mendel Medical Corporation United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Fresenius Kabi USA, LLC, please visit www.apppharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.